Dr Emma Meczes Huw Thomas Professor Richard Edmondson Professor Gareth Veal Professor Alan Boddy et al. | Therapy induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tumours | 2012 |
|
Dr Emma Meczes Kathryn Gilroy Professor Caroline Austin
| The impact of the human DNA topoisomerse II C-terminal domain on activity | 2008 |
|
Dr Emma Meczes Ali Azim-Araghi Dr Michael Tilby
| Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA | 2005 |
|
Dr Emma Meczes Professor Andrew Pearson Professor Caroline Austin Dr Michael Tilby
| Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin | 2002 |
|
Dr Emma Meczes Professor Andrew Pearson Dr Michael Tilby
| Characterisation of the DNA damage recognised by a monoclonal antibody raised against cisplatin-modified DNA | 2001 |
|
Dr Emma Meczes Professor Caroline Austin
| Mutagenesis of E477 or K505 in the B' domain of human topoisomerase IIβ increases the requirement for magnesium ions during strand passage | 2000 |
|
Dr Emma Meczes Dr Margaret Rogers Professor Caroline Austin
| Carbamate analogues of amsacrine active against non-cycling cells: Relative activity against topoisomerases IIα and β | 1999 |
|
Dr Emma Meczes Professor Caroline Austin Professor Andrew Pearson Dr Michael Tilby
| Synergy studies of etoposide and cisplatin action in neuroblastoma cell lines | 1999 |
|
Dr Emma Meczes Professor Caroline Austin
| 103 Site-directed mutagenesis of human DNA topoisomerase IIβ | 1997 |
|
Dr Emma Meczes Dr Margaret Rogers Professor Caroline Austin
| Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2β construct allows the study of topoisomerase IIβ inhibitors in yeast | 1997 |
|
Dr Elaine Willmore Dr Emma Meczes Professor Caroline Austin
| Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms α and β | 1996 |
|